Table 5.
SIR, RR and AER for subsequent primary malignant neoplasms (SPNs) of the tongue by different factors among all cancer survivors in the PanCareSurFup cohort.
| SPN on tongue | Level | Obs (%) | Exp | SIR (95% CI) | RR (95%CI) | AER (95% CI) |
|---|---|---|---|---|---|---|
| Overall | 38 (100%) | 6.4 | 5.9 (4.7–7.4) | – | 2.5 (1.9–3.3) | |
| Sexa | Male | 24 (63%) | 4.2 | 5.7 (3.8–8.5) | 1.0 (ref) | 2.9 (1.8–4.8) |
| Female | 14 (37%) | 2.2 | 6.5 (3.8–10.9) | 0.9 (0.4–1.7) | 2.0 (1.1–3.7) | |
| pheterogeneity | 0.70 | 0.65 | 0.34 | |||
| Type of childhood cancera | Leukaemia | 17 (45%) | 0.7 | 25.7 (16.0–41.4) | 1.4 (0.5–3.9) | 6.3 (3.9–10.4) |
| Hodgkin lymphoma | 2 (5%) | 0.7 | 3.1 (0.8–12.2) | 0.3 (0.1–1.4) | 1.4 (0.2–10.8) | |
| Non-HL | 0 (0%) | 0.4 | – | – | – | |
| CNS tumour | 0 (0%) | 1.5 | – | – | – | |
| Neuroblastoma | 1 (3%) | 0.2 | 5.2 (0.7–36.8) | 0.6 (0.1–5.0) | 1.3 (0.1–14.8) | |
| Retinoblastoma | 1 (3%) | 0.4 | 2.6 (0.4–18.3) | 0.5 (0.0–4.3) | 0.9 (0.0–21.4) | |
| Wilms tumour | 2 (5%) | 0.4 | 5.0 (1.3–20.0) | 0.5 (0.1–2.9) | 1.5 (0.3–8.3) | |
| Bone sarcoma | 6 (16%) | 0.4 | 14.3 (6.4–31.7) | 1.4 (0.4–4.6) | 9.8 (4.2–23.2) | |
| Soft tissue sarcoma | 5 (13%) | 0.6 | 8.7 (3.6–21.0) | 1.0 (ref)) | 4.8 (1.8–12.9) | |
| Other | 4 (11%) | 1.1 | 3.7 (1.4–9.8) | 0.4 (0.1–1.6) | 1.6 (0.4–6.0) | |
| pheterogeneity | <0.001 | <0.001 | <0.001 | |||
| Decade of childhood cancer diagnosisa | <1970 | 5 (13%) | 3.4 | 1.5 (0.6–3.5) | 1.0 (ref) | 0.5 (0.0–8.3) |
| 1970–1979 | 13 (34%) | 1.7 | 7.4 (4.3–12.8) | 2.6 (0.8–8.8) | 3.2 (1.7–6.0) | |
| 1980–1989 | 16 (42%) | 1.0 | 16.5 (10.1–27.0) | 3.7 (0.9–14.9) | 3.8 (2.2–6.3) | |
| 1990–2008 | 4 (11%) | 0.2 | 16.0 (6.0–42.6) | 2.2 (0.4–12.9) | 1.9 (0.7–5.3) | |
| ptrend | <0.001 | 0.35 | 0.07 | |||
| Age at childhood cancer (years)a | 0–3 | 9 (24%) | 1.4 | 6.6 (3.4–12.7) | 1.0 (ref) | 1.7 (0.8–3.8) |
| 4–7 | 6 (16%) | 1.1 | 5.4 (2.4–12.1) | 0.9 (0.3-2.6) | 1.8 (0.7-4.7) | |
| 8–11 | 13 (34%) | 1.3 | 9.8 (5.7–17.0) | 2.3 (0.8–6.8) | 5.6 (3.0–10.2) | |
| 12–21 | 10 (26%) | 2.6 | 3.8 (2.1–7.1) | 1.1 (0.3–4.5) | 2.2 (0.9–5.0) | |
| ptrend | 0.36 | 0.65 | 0.30 | |||
| Attained age (years)a | <20 | 2 (5%) | 0.1 | 35.6 (8.9–142.3) | 1.0 (ref) | 0.5 (0.1–2.0) |
| 20–29 | 14 (37%) | 0.7 | 20.8 (12.3–35.1) | 0.6 (0.1–2.8) | 3.2 (1.8–5.5) | |
| 30–39 | 11 (29%) | 1.3 | 8.8 (4.9–15.9) | 0.3 (0.1–1.4) | 3.7 (1.9–7.2) | |
| 40–49 | 7 (18%) | 1.9 | 3.6 (1.7–7.6) | 0.2 (0.0–1.0) | 4.2 (1.5–11.7) | |
| 50+ | 4 (11%) | 2.5 | 1.6 (0.6–4.3) | 0.2 (0.0–1.2) | 2.9 (0.2–38.1) | |
| ptrend | <0.001 | 0.01 | 0.003 | |||
| Time since 5-year survival (years)b | 0–9 | 7 (18%) | 0.4 | 20.0 (9.5–41.9) | 1.0 (ref) | 1.2 (0.5–2.6) |
| 10–19 | 12 (32%) | 0.9 | 13.0 (7.4–22.9) | 0.5 (0.2–1.4) | 3.0 (1.6–5.5) | |
| 20–29 | 10 (26%) | 1.6 | 6.2 (3.3–11.5) | 0.3 (0.1–0.9) | 3.9 (1.9–8.3) | |
| 30+ | 9 (24%) | 3.5 | 2.6 (1.3–4.9) | 0.3 (0.1–1.2) | 4.8 (1.6–13.9) | |
| ptrend | <0.001 | 0.07 | 0.02 | |||
| Radiotherapy for childhood cancerc,d | Yes | 18 (64%) | 2.9 | 6.3 (4.0–10.0) | 1.0 (0.4–2.4) | 3.2 (1.9–5.6) |
| No | 8 (29%) | 1.4 | 5.7 (2.8–11.4) | 1.0 (ref) | 2.5 (1.1–5.8) | |
| Unknown | 2 (7%) | – | – | – | – | |
| pheterogeneity | 0.80 | 0.92 | 0.62 | |||
| Chemotherapy for childhood cancerc,d | Yes | 24 (86%) | 1.5 | 15.9 (10.6–23.7) | 5.6 (1.0–31.2) | 5.0 (3.3–7.7) |
| No | 2 (7%) | 2.6 | 0.8 (0.2–3.1) | 1.0 (ref) | – | |
| Unknown | 2 (7%) | – | – | – | – | |
| pheterogeneity | <0.001 | 0.03 | <0.001 |
Pyrs person-years, Obs observed, Exp expected, SIR standardised incidence ratio, RR relative risk, AER absolute excess risks, HL Hodgkin lymphoma.
aRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.
bRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow-up time.
cRRs were derived from a model including sex, country, age at childhood diagnosis, attained age and treatment.
dExcluded Nordic countries (Denmark, Sweden, Norway, Finland, Iceland) and Italy population-based data because of lack of treatment data.